Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer
Launched by APREA THERAPEUTICS · May 12, 2009
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Summary criteria for participant selection:
- Inclusion Criteria:
- • Male or female ≥ 18 years of age.
- * Any below mentioned advanced disease, which is not eligible for other therapies. The diagnosis should have been confirmed either histologically or cytologically:
- • 1. Acute myeloid leukemia.
- • 2. Acute lymphoid leukemia.
- • 3. Chronic lymphocytic leukemia.
- • 4. Chronic myeloid leukemia.
- • 5. Chronic myelomonocytic leukemia.
- • 6. Multiple myeloma.
- • 7. Non Hodgkin's lymphoma.
- • 8. Hodgkin's lymphoma.
- • 9. Myelodysplastic syndrome.
- • 10. Myelofibrosis.
- • 11. Hormone refractory, metastatic prostate carcinoma.
About Aprea Therapeutics
Aprea Therapeutics is a biotechnology company focused on advancing innovative therapies for cancer treatment through the development of novel small molecules that target the p53 tumor suppressor pathway. With a commitment to addressing unmet medical needs, Aprea harnesses its expertise in drug discovery and clinical development to bring forward potentially transformative treatments for patients with various malignancies. The company emphasizes a rigorous scientific approach and collaboration with leading research institutions to drive its clinical programs and enhance patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Göteborg, , Sweden
Stockholm, , Sweden
Uppsala, , Sweden
Uppsala, , Sweden
örebro, , Sweden
örebro, , Sweden
Patients applied
Trial Officials
Sören Lehmann, MD, PhD
Principal Investigator
Hematology Centre, M54, Karolinska Institute, Karolinska University Hospital, Huddinge, SE-141 86, Stockholm, Sweden
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials